Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.
Novartis AG has presented detailed data on its latest multiple sclerosis drug ofatumumab which the company believes will provide a more convenient treatment for patients than Roche's rival therapy Ocrevus.
Having published positive topline results last month, Novartis presented the full data set from the Phase III ASCLEPIOS I and...
Oral RNA splicing modulator has gone into a Phase II/III trial
Wales-based group launches with $140m series A.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
